A Fast Algorithm for Estimating Two-Dimensional Sample Entropy Based on an Upper Confidence Bound and Monte Carlo Sampling.

The two-dimensional sample entropy marks a significant advance in evaluating the regularity and predictability of images in the information domain. Unlike the direct computation of sample entropy, which incurs a time complexity of O(N2) for the series with N length, the Monte Carlo-based algorithm for computing one-dimensional sample entropy (MCSampEn) markedly reduces computational costs by minimizing the dependence on N. This paper extends MCSampEn to two dimensions, referred to as MCSampEn2D. This new approach substantially accelerates the estimation of two-dimensional sample entropy, outperforming the direct method by more than a thousand fold. Despite these advancements, MCSampEn2D encounters challenges with significant errors and slow convergence rates. To counter these issues, we have incorporated an upper confidence bound (UCB) strategy in MCSampEn2D. This strategy involves assigning varied upper confidence bounds in each Monte Carlo experiment iteration to enhance the algorithm's speed and accuracy. Our evaluation of this enhanced approach, dubbed UCBMCSampEn2D, involved the use of medical and natural image data sets. The experiments demonstrate that UCBMCSampEn2D achieves a 40% reduction in computational time compared to MCSampEn2D. Furthermore, the errors with UCBMCSampEn2D are only 30% of those observed in MCSampEn2D, highlighting its improved accuracy and efficiency.

Model-based assessment of mammalian cell metabolic functionalities using omics data.

Omics experiments are ubiquitous in biological studies, leading to a deluge of data. However, it is still challenging to connect changes in these data to changes in cell functions because of complex interdependencies between genes, proteins, and metabolites. Here, we present a framework allowing researchers to infer how metabolic functions change on the basis of omics data. To enable this, we curated and standardized lists of metabolic tasks that mammalian cells can accomplish. Genome-scale metabolic networks were used to define gene sets associated with each metabolic task. We further developed a framework to overlay omics data on these sets and predict pathway usage for each metabolic task. We demonstrated how this approach can be used to quantify metabolic functions of diverse biological samples from the single cell to whole tissues and organs by using multiple transcriptomic datasets. To facilitate its adoption, we integrated the approach into GenePattern (www.genepattern.org-CellFie).

Prediction of human major histocompatibility complex class II binding peptides by continuous kernel discrimination method.

OBJECTIVE: Accurate prediction of major histocompatibility complex (MHC) class II binding peptides helps reducing the experimental cost for identifying helper T cell epitopes, which has been a challenging problem partly because of the variable length of the binding peptides. This work is to develop an accurate model for predicting MHC-binding peptides using machine learning methods. METHODS: In this work, a machine learning method, continuous kernel discrimination (CKD), was used for predicting MHC class II binders of variable lengths. The composition transition and distribution features were used for encoding peptide sequence and the Metropolis Monte Carlo simulated annealing approach was used for feature selection. RESULTS: Feature selection was found to significantly improve the performance of the model. For benchmark dataset Dataset-1, the number of features is reduced from 147 to 24 and the area under the receiver operating characteristic curve (AUC) is improved from 0.8088 to 0.9034, while for benchmark dataset Dataset-2, the number of features is reduced from 147 to 44 and the AUC is improved from 0.7349 to 0.8499. An optimal CKD model was derived from the feature selection and bandwidth optimization using 10-fold cross-validation. Its AUC values are between 0.831 and 0.980 evaluated on benchmark datasets BM-Set1 and are between 0.806 and 0.949 on benchmark datasets BM-Set2 for MHC class II alleles. These results indicate a significantly better performance for our CKD model over other earlier models based on the training and testing of the same datasets. CONCLUSIONS: Our study suggested that the CKD method outperforms other machine learning methods proposed earlier in the prediction of MHC class II biding peptides. Moreover, the choice of the cut-off for CKD classifier is crucial for its performance.